CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang
Cancer Research and Treatment. 2018;50(1):195-203.   Published online 2017 March 21    DOI: https://doi.org/10.4143/crt.2016.376

Excel Download

An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016)
Journal of Gynecologic Oncology. 2017;28(3):   Crossref logo
Link1 Link2 Link3

Multi-institutional Phase I clinical trial of cremophor-free, polymeric micelle formulation of paclitaxel (Genexol-PM) with carboplatin for patients with advanced epithelial ovarian cancer
Gynecologic Oncology. 2012;125:S32   Crossref logo
Link1 Link2

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour I'Etude des Cancers Ovariens
Yearbook of Oncology. 2007;2007:69-70   Crossref logo
Link1 Link2

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study
Yearbook of Oncology. 2007;2007:82-83   Crossref logo
Link1 Link2

Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer
Gynecologic Oncology. 2001;81(2):331-333   Crossref logo
Link1 Link2

An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
Cancer Research and Treatment. 2017;49(3):569-577   Crossref logo
Link1 Link2 Link3

A Randomized Phase II Study of Paclitaxel With Carboplatin ± Amifostine as First Line Treatment in Advanced Ovarian Carcinoma
Yearbook of Oncology. 2006;2006:111   Crossref logo
Link1 Link2

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO
Yearbook of Oncology. 2007;2007:70-71   Crossref logo
Link1 Link2

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer
Journal of Thoracic Oncology. 2011;6(1):109-114   Crossref logo
Link1 Link2

Impact of cytokine use on survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group study
Gynecologic Oncology. 2012;125:S29   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.